Bionomics Limited is a clinical-stage biopharmaceutical company based in Thebarton, Australia, specializing in the discovery and development of innovative therapeutics for central nervous system disorders and cancer. The company's portfolio includes several drug candidates, with its lead product, BNC210, a negative allosteric modulator aimed at treating anxiety, panic, agitation, and post-traumatic stress disorder, having completed a phase 2 clinical trial. Additionally, Bionomics is developing BNC375, targeting cognitive impairment in Alzheimer's disease, and BNC101, a monoclonal antibody that has completed phase 1 trials aimed at cancer stem cells. The company is also advancing BNC105, a vascular disrupting agent currently undergoing phase 2 trials for refractory colorectal cancer and phase 1 trials for relapsed/refractory chronic lymphocytic leukemia. Bionomics further enhances its capabilities through the ionX platform, which integrates genomics discoveries and technologies. Founded in 1996, the company has established strategic partnerships to bolster its research and development efforts.
Prestwick Chemical is a French Contract Research Organization (CRO) established in 1999 by Professor C.G. Wermuth, a noted expert in pharmacology and medicinal chemistry. The company specializes in early drug discovery, offering smart chemical screening libraries and medicinal chemistry services aimed at accelerating the development of innovative small molecule drugs. Prestwick Chemical serves a diverse clientele, including pharmaceutical and biotechnology companies, research institutes, and academic groups, and also engages in projects related to cosmetics, veterinary medicine, and agro-pharmaceuticals. Over the past decade, the company has gained international recognition for enhancing the drug discovery process through tailor-made services and a portfolio designed to maximize chemical diversity, thereby improving the chances of success in hit finding and fragment-based drug discovery.
Eclipse Therapeutics
Acquisition in 2012
Eclipse Therapeutics, Inc. is a private biotechnology company focused on discovering and developing innovative therapeutics aimed at targeting cancer stem cells (CSCs) and other cancer treatment modalities. The company utilizes a unique biotechnology platform to create novel therapeutic products designed to address the complexities of cancer treatment. Through its commitment to advancing cancer therapies, Eclipse Therapeutics seeks to improve patient outcomes and contribute to the ongoing fight against cancer.
Iliad Chemicals Pty
Acquisition in 2005
Iliad Chemicals Pty Limited develops a library of novel molecules that act as potent tubulin polymerisation inhibitors for treating cancer. The company utilizes MultiCore Chemistry technology platform to provide synthesis of molecules and develop chemical libraries.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.